# Prostate cancer: why similar diagnoses can lead to different treatments

Active surveillance, robotic surgery, focused ultrasound or a clinical trial: during Novembro Azul, Brazil's prostate cancer awareness month, oncologists explain how the tumor's aggressiveness, age and each patient's life set the course, and why monitoring is not the same as not treating.

- Section: Health
- Published: November 21, 2026
- Address: https://ceoone.com.br/en/article/prostate-cancer-why-similar-diagnoses-can-lead-to-different-treatments
- Em português: https://ceoone.com.br/artigo/cancer-de-prostata-por-que-diagnosticos-parecidos-podem-levar-a-tratamentos-diferentes.md

![A urologist talks with a man in his early sixties, in a navy sweater, in a doctor's office; on the desk, a blue Novembro Azul ribbon and a tablet with a drawing of the prostate](https://pub-b80e49b2737940b3ab5d3f20d0578192.r2.dev/artigos/cancer-de-prostata-por-que-diagnosticos-parecidos-podem-levar-a-tratamentos-diferentes-consulta.webp)

AI-generated

## Key points

- Inca estimates 77,920 new prostate cancer cases a year through 2028, 30.5% of cancer diagnoses in men.
- Low risk tumors can stay under active surveillance; aggressiveness, age and the patient's health set the treatment.
- Robotic surgery, HIFU and new drugs widened the options, and clinical trials are an alternative in some cases.

Ivan Gomes Filho had routine checkups at the start of every year. In 2020, the pandemic pushed his appointment to December, when he found out he had prostate cancer. "On a scale of zero to ten, it was already at nine", recalls Ivan, now 72.

In March 2021, Ivan had surgery at Hospital Nove de Julho, in São Paulo, and 34 radiotherapy sessions. In the following years, he was monitored every three months by oncologist Carlos Dzik, head of genitourinary tumors at Rede Américas, and received drugs to hold back his rising PSA. When one of them stopped working as expected, the doctor recommended another path: a clinical trial underway at the research center of Hospital Samaritano Higienópolis.

"I come from a time when, if cancer was confirmed in someone in the family, people said the patient was beyond hope. I am living proof that this has changed", Ivan says.

Brazil's National Cancer Institute (Inca) estimates 77,920 new cases of prostate cancer a year between 2026 and 2028, or 30.5% of cancer diagnoses in men, excluding non melanoma skin tumors. Each patient's path depends on the tumor and on their health.

## Choosing the treatment

For Dzik, gauging how aggressive the cancer is shapes the approach. Low risk tumors, slow growing and confined to the prostate, are often monitored without immediate intervention. "In active surveillance, we repeat tests and watch for signs of progression to decide when to step in", he explains.

The PSA, a blood test that measures a protein made by the prostate, flags but does not on its own confirm cancer. When there is a suspicion, the recommendation is a multiparametric MRI, which produces detailed images of the gland, and a biopsy. Tissue analysis also grades the tumor's aggressiveness, which is weighed along with age, life expectancy and overall health when choosing treatment.

## Surgery and technology

A Latin American reference in robotic surgery, Hospital Nove de Julho became, in 2025, the first non philanthropic hospital in Latin America to reach 10,000 robotic procedures. "Robotic surgery has the advantage of being minimally invasive, with less pain, faster recovery, discharge within 24 hours and an earlier return to normal activities", says urologist Rafael Coelho, of the hospital.

In a study at the University of São Paulo, with Coelho's participation, urinary incontinence after one year was below 5% among patients operated on robotically, against 22% in open surgery. Results also depend on the surgeon's experience and on the tumor.

For selected cases of localized cancer, there is also HIFU, high intensity focused ultrasound, a minimally invasive option regulated by Brazil's Federal Council of Medicine in May 2026.

## When the disease advances

Metastases change the strategy. New drugs have widened the options to control advanced prostate cancer, extend survival and preserve quality of life.

The choice takes into account how far each case has spread and the treatments already given. "We are progressively turning this disease into a chronic condition, although that does not mean curing it", explains Fernando Vidigal de Pádua, a clinical oncologist at Hospital Brasília.

That was when Ivan joined a clinical trial, the research that tests a treatment's safety and efficacy before it is approved for wide use. Across the network, more than 250 trials are underway, with more than 2,500 participants.

## From screening to treatment

The path, step by step, from the first visit to follow up after treatment.

![Infographic with seven steps of prostate cancer care, each with an icon: when to see a doctor, which tests, a high PSA, a confirmed diagnosis, treatment options, clinical research and follow up](https://pub-b80e49b2737940b3ab5d3f20d0578192.r2.dev/artigos/cancer-de-prostata-por-que-diagnosticos-parecidos-podem-levar-a-tratamentos-diferentes-infografico-en.webp)

Icons: reproduction/O Estado de S. Paulo

In December, Ivan will have the test that will show how the disease responded to treatment. While he waits, he repeats his advice: "Take care of your health as early as possible, and don't be embarrassed".

## Sources and editorial notes

- O Estado de S. Paulo, Pulsa section, "As decisões no câncer de próstata", 11/21/2026, with Carlos Dzik, Rafael Coelho and Fernando Vidigal de Pádua.
- Brazil's National Cancer Institute (Inca), 2026-2028 estimate.

CEO ONE · https://ceoone.com.br

